Skip to main content
Fig. 2 | Molecular Medicine

Fig. 2

From: Hypermethylation of TMEM240 predicts poor hormone therapy response and disease progression in breast cancer

Fig. 2

TMEM240 is localized in the cytoplasm and membrane and represses cancer cell growth and migration in breast cancer cells. A recombinant pMyc-DDK-hTMEM240 plasmid was transfected into MDA-MB-231 breast cancer cells (A) and T47D breast cancer cells (B) for 24 h, and the cells were then analyzed via immunofluorescence for TMEM240 protein (left, original magnification, × 200) and real-time RT–PCR for mRNA expression (middle). The proliferation of the MDA-MB-231 and T47D cells was analyzed using sulforhodamine B (SRB) assays (right). si-TMEM240 was transfected into MDA-MB-231 cells (C) and T47D cells (D). The cell morphology (left, original magnification, × 100), mRNA expression (middle), and rate of cell proliferation (right) of the breast cancer cells were analyzed. E The migratory ability of MDA-MB-231 cells after TMEM240 overexpression was measured via transwell assays. si-TMEM240 was transfected into MDA-MB-231 cells for 24 h, and the distribution of the cells was then analyzed using transwell assays (F) and wound healing assays (G). The data are presented as the mean ± SD; *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001. A t-test was used to calculate group differences in all experiments. Experiments were performed using at least two biological duplicates and three technical replicates. Localization of the TMEM240 protein was determined by deconvolution and 3D reconstruction. H Recombinant pMyc-DDK vector control. I The recombinant pMyc-DDK-hTMEM240 plasmid was transfected into the cells for 24 h. Red, anti-Myc-hTMEM240 protein. Green, anti-DDK-hTMEM240 protein. Blue, DAPI staining

Back to article page